Liposomes have been intensively investigated and serve as one of the most biocompatible biomedical drug delivery systems for clinical applications1,2. They are mainly composed of phospholipids and cholesterol, both of which are biocompatible compounds mimicking parts of natural cell membranes. Whereas hydrophilic substances can be entrapped in the aqueous interior, lipophilic agents can be incorporated within the liposomal phospholipid bilayer3. Encapsulation of substances within the aqueous interior of liposomes grants protection against degradation in vivo and also prevents the host system from toxic effects of cytotoxic drugs used for the therapy of diseases, for example chemotherapeutics aimed at destroying tumor cells. The modification of the liposomal surface with polymers like polyethylenglycol (PEGylation) further extends the liposomal blood circulation time in vivo due to sterical stabilization4. Moreover, liposomes can sequester high concentrations of several substances such as proteins5,6, hydrophilic substances7,8 and enzymes9. They therefore serve as reliable clinical therapeutic and diagnostic tools which merit their approval for delivery of cytotoxic drugs such as doxorubicin for cancer therapy4. Due to their flexibility, liposomes can also be loaded with fluorochromes for diagnostic and image-guided surgical purposes.
Fluorescence imaging provides a cost-effective and non-invasive in vivo diagnostic tool which however, demands some basic requirements. It could be demonstrated that fluorochromes which suit best for in vivo imaging have characteristic absorption and emission maxima in the range where light dispersion and scattering as well as tissue autofluorescence originating from water and hemoglobin is low. Thus, such probes have their abs/em maxima between 650 and 900 nm10. Besides this, the stability of fluorochromes both in vitro and in vivo is critical, as opsonization and rapid clearance can greatly limit their application for in vivo imaging11. Other effects such as poor stability and low sensitivity or cytotoxic effects on target organs as seen with indocyanine green (ICG)12-16, are unwanted and must be taken into consideration when designing probes for in vivo imaging. These observations have led to the active development of several preclinical NIR fluorochromes, nanoparticles as well as new techniques for the in vivo imaging of inflammatory processes, cancer and for image-guided surgery17-20. Despite the stability of most preclinical NIRF (near-infrared fluorescence) dyes in vitro, their rapid perfusion and clearance through the liver and kidney impede their use in the in vivo optical imaging of diseases and inflammatory processes.
We therefore present a protocol for the encapsulation of fluorochromes such as the well characterized near-infrared fluorescent dye DY-676-COOH, known for its tendency to self-quench at relatively high concentrations21 in liposomes. At high concentrations H-dimer formation and/or pi-stacking interactions between fluorophore molecules located within each other’s Förster radius result in Förster resonance energy transfer (FRET) between the fluorochrome molecules. At low concentration the space between the fluorophore molecules increases, thereby preventing pi-stacking interaction and H-dimer formation and resulting in high fluorescence emission. The switch between high and low concentration and the accompanying fluorescence quenching and activation is a promising strategy that can be exploited for optical imaging22. In this respect, encapsulation of high concentrations of the NIRF dye DY-676-COOH in the aqueous interior of liposomes is more favorable for in vivo imaging than the free dye. The challenge of the method lies first of all in the correct encapsulation and secondly, in the validation of the benefits resulting from encapsulating high concentrations of the dye. Comparing the imaging properties of quenched liposomes with that of the free dye and also with a non-quenched liposome formulation with low concentrations of the dye is indispensable. We show by a simple, but highly effective film hydration and extrusion protocol combined with alternate freeze and thaw cycles that encapsulation of quenching concentrations of DY-676-COOH in liposomes is feasible. Other methods used to prepare liposomes such as the reversed phase evaporation method23 as well as the ethanol injection method24 enable liposome preparation with high encapsulation efficiencies for many hydrophilic substances. However, the nature of the substance to be encapsulated can influence the encapsulation efficiency. In effect, the film hydration and extrusion protocol presented here revealed the highest efficiency for encapsulation of DY-676-COOH. To illustrate the benefits of liposomal encapsulation of DY-676-COOH, a zymosan-induced edema model, which permits the study of inflammatory processes within a few hours, was used. Here, it is demonstrated that liposomes with high concentrations of the encapsulated DY-676-COOH are more suitable for whole body in vivo optical imaging of inflammatory processes than the free dye or the non-quenched liposomal formulation with low dye concentrations. Thus the underlying protocol provides a simple and fast method to produce quenched fluorescent liposomes and the validation of their activation and imaging potential both in vitro and in vivo.